Endoscopy Systems Market to Reach $4.5 Billion by 2015, According to New Report by Global Industry Analysts, Inc.

Endoscopy Systems Market to Reach $4.5 Billion by 2015, According to New Report by Global Industry Analysts, Inc.

The market for endoscopy systems is projected to reach $4.5 billion by 2015. Growth in this dynamic market is driven by increasing acceptance of endoscopic techniques among physicians, extensive use of endoscopy procedures and technology advancements in areas such as robotics, miniaturization, and imaging.

San Jose, CA (PRWEB) February 19, 2009 -- Endoscopy systems occupy a significant position in the medical device market with applications extending over several areas in medical surgery. The market is driven by an aging population, demand for preventive screening procedures such as colorectal screening, and growing awareness among people towards this medical discipline. Endoscopic procedures are less risky, less painful, and involve lesser patient recovery period, when compared to traditional methods. Owing to escalating opportunities and demand for Minimally Invasive Endoscopy Surgery (MIES) procedures, several medical equipment manufacturers are focusing on developing products that are highly capable of offering minimally invasive surgeries.

US, Japan, and Europe comprise the largest markets, accounting for a major share of the global endoscopy systems market (http://www.strategyr.com/Endoscopy_Systems_Market_Report.asp), as stated in a recent report published by Global Industry Analysts, Inc. Asia-Pacific with increasing penetration of endoscopy procedures represents a potential market for endoscopy systems with CAGR of 5.8% for the next few years. An expanding chronically ill and aging population, improvements in endoscopy technologies and advancements in minimally invasive surgery technologies are driving the endoscopes (http://www.strategyr.com/Endoscopy_Systems_Market_Report.asp) market in the region. Globally, the market for Visualization equipment (http://www.strategyr.com/Endoscopy_Systems_Market_Report.asp) is largely driven by technological advancements such as high-definition camera systems, NBI, MBI technologies, and advancement in video processing, recording, and communication technologies.

Among the application areas, gastrointestinal endoscopy is rapidly trenching new opportunities with growing demand for initial cancer screening tests that facilitates survival prospects of the patient before the risk of metastasis. The segment is also driven by advancements such as capsule endoscopy, which is finding useful application in imaging the gastrointestinal tract including the small intestine. Growth in the market is expected to be further driven by release of novel products and expanding product indications.

The global marketplace is characterized by presence of players such as Boston Scientific Corporation, Conmed Corporation, Ethicon Endo-Surgery, Inc., Fujinon Corp., Given Imaging, Hoya Corporation, Karl Storz GmbH & Co. KG, Medtronic Neurologic Technologies, Olympus Corporation, Richard Wolf Medical Instruments Corporation, Smith & Nephew Plc, and Stryker Corporation.

"Endoscopy Systems: A Global Strategic Business Report", published by Global Industry Analysts, Inc. provides a comprehensive review of major market dynamics, trends, technology advancements, and competition pertaining to the market. The report enumerates recent product introductions/innovations, developments, mergers, acquisitions and other strategic industry activities. Product segments analyzed in the study include Endoscopes and Visualization Equipment. Analysis is presented for the periods 1995-2005 and 2006-2015 for established and emerging markets including the United States, Canada, Japan, France, Germany, United Kingdom, Italy, Spain, Asia-Pacific and Latin America.

For more details about this research report, please visit http://www.strategyr.com/Endoscopy_Systems_Market_Report.asp

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) (http://www.strategyr.com) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs more than 700 people worldwide and publishes more than 880 full-scale research reports each year. Additionally, the company also offers a range of more than 60,000 smaller research products including company reports, market trend reports and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.

Telephone 408-528-9966

Fax 408-528-9977

Web Site http://www.StrategyR.com

###

Contact Information Public Relations

Global Industry Analysts, Inc.

http://www.StrategyR.com/

(408) 528-9966

Landmark Trial Provides Vital Information for Cardiac Disease Treatment

Landmark Trial Provides Vital Information for Cardiac Disease Treatment

NorthShore University HealthSystem Ted Feldman, M.D., Lead Investigator

Evanston, IL. -- NorthShore University HealthSystem (http://www.northshore.org/) (NorthShore) has played a leading role in a landmark clinical trial comparing two forms of treatment for patients with severe coronary artery disease (CAD). The results were published on-line in this week's issue of the New England Journal of Medicine.

The SYNTAX trial was a clinical research study that compared percutaneous coronary intervention (PCI) with drug-eluting stents and coronary artery bypass surgery (CABG) in patients with three-vessel and left main coronary disease. The trial results did not show any statistically significant differences between PCI and CABG in rates of death or heart attack, an excess of stroke in the CABG treated patients, and a greater need for repeat PCI procedures in the stent treated patients. These are better outcomes for PCI than have been seen in prior trials in less complex patients.

"At NorthShore, we experienced stunning outcomes in patients whose only option would have previously been bypass surgery," said Ted Feldman, M.D, F.S.C.A.I., Director of Cardiac Catheterization Laboratory, NorthShore University HealthSystem, and a lead investigator of the trial. "The data in this study will provide cardiologists with additional information as they determine treatment therapy for patients with complex CAD."

The trial is the first randomized, controlled clinical trial to compare these two treatments in patients with left main disease and/or three-vessel disease, who are typically treated with CABG and represent a population with far more complex anatomy and advanced disease than those studied in prior drug-eluting stent (DES) clinical trials.

There were 1,800 patients enrolled in the randomized arm of the trial. All patients were assessed by a multidisciplinary team including an interventional cardiologist and a cardiac surgeon. If both the cardiologist and surgeon felt that they could offer equivalent complete revascularization, patients were randomized 1:1 into one of the two treatment strategies. If either the cardiologist or surgeon felt that one or the other revascularization technique was the preferred option, due to technical considerations or co-morbidity, for example, then patients were recruited into one of two parallel, nested registries for PCI or CABG. Thus, patients in the PCI registry had been rejected for cardiac surgery.

About NorthShore University HealthSystem

Headquartered in Evanston, Ill., NorthShore University HealthSystem (NorthShore) is a comprehensive, fully integrated, healthcare delivery system that serves the greater North Shore and northern Illinois communities. The system includes three Hospitals--Evanston Hospital, Glenbrook Hospital and Highland Park Hospital--and a fourth, Skokie-based Rush North Shore Hospital, to be added in January 2009. In addition, the healthsystem has more than 2,000 affiliated physicians, including a 550-physician, multispecialty physician group practice with over 70 office locations-- NorthShore University HealthSystem Medical Group. Further, NorthShore is committed to excellence in its academic mission and supports teaching and research as the principal teaching affiliate of the University of Chicago's Pritzker School of Medicine. The NorthShore University HealthSystem Research Institute, with more than $100 million of grants, focuses on clinical and translational research, including leadership in outcomes research and clinical trials.

NorthShore has annual revenues of $1.5 billion and a staff of more than 8,000. The healthsystem has significant capabilities in a wide spectrum of clinical programs, including cancer, heart, orthopaedics, high-risk maternity and pediatrics. NorthShore is a national leader in the implementation of innovative technologies, including electronic medical records, (EMR ). In 2003, the healthsystem was among the first in the country to successfully launch a systemwide EMR with demonstrable benefits in quality, safety, efficiency and service to patients. NorthShore has been recognized by multiple national organizations for this notable achievement. Visit http://www.northshore.org/

CONTACT: Amy Ferguson

Senior Director, Public Relations

NorthShore University HealthSystem

(847) 570-3146

###

Contact Information Amy Ferguson

Northshore University HealthSystem

http://www.northshore.org/

847-570-3146